The estimated Net Worth of Michael Hyatt is at least $532 ezer dollars as of 1 March 2016. Mr. Hyatt owns over 3,413 units of Endo International plc stock worth over $73,237 and over the last 11 years he sold ENDP stock worth over $143,994. In addition, he makes $315,000 as Independent Director at Endo International plc.
Sign up
Mr. Hyatt ENDP stock SEC Form 4 insiders trading
Michael has made over 3 trades of the Endo International plc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 3,413 units of ENDP stock worth $143,994 on 1 March 2016.
The largest trade he's ever made was exercising 10,000 units of Endo International plc stock on 11 November 2015 worth over $314,300. On average, Michael trades about 2,128 units every 51 days since 2014. As of 1 March 2016 he still owns at least 250,297 units of Endo International plc stock.
You can see the complete history of Mr. Hyatt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Hyatt biography
Michael Hyatt is an Independent Director of Endo International Public Limited Company. He has been a member of the Board of Directors since February 2014 and is Chair of Endo’s Nominating & Governance Committee and a member of Endo’s Compensation Committee. Mr. Hyatt has been a Senior Advisor to Irving Place Capital since 2008. Prior to 2008, Mr. Hyatt was a Senior Managing Director of Bear Stearns & Co., Inc. Mr. Hyatt previously served as a Director of Schiff Nutrition International until 2012. From 2000 until February 2014, Mr. Hyatt was a Director of Endo Health Solutions Inc. Mr. Hyatt holds a Bachelor of Arts degree from Syracuse University and a J.D. degree, from Emory University School of Law. Mr. Hyatt’s qualifications to serve on the Board of Endo include, among others, his leadership experience in the banking industries, in-depth knowledge of the Company and experience as a board member of a publicly traded company.
What is the salary of Michael Hyatt?
As the Independent Director of Endo International plc, the total compensation of Michael Hyatt at Endo International plc is $315,000. There are 12 executives at Endo International plc getting paid more, with Paul Campanelli having the highest compensation of $13,118,300.
How old is Michael Hyatt?
Michael Hyatt is 74, he's been the Independent Director of Endo International plc since 2014. There are no older and 16 younger executives at Endo International plc.
What's Michael Hyatt's mailing address?
Michael's mailing address filed with the SEC is 745 FIFTH AVENUE, 7TH FLOOR, , NEW YORK, NY, 10151.
Insiders trading at Endo International plc
Over the last 11 years, insiders at Endo International plc have traded over $3,455,441 worth of Endo International plc stock and bought 152,347 units worth $3,901,804 . The most active insiders traders include Silva Rajiv De, Paul Campanelli és Shane Cooke. On average, Endo International plc executives and independent directors trade stock every 36 days with the average trade being worth of $12,163. The most recent stock trade was executed by Patrick A Barry on 29 March 2022, trading 59,298 units of ENDP stock currently worth $17,351.
What does Endo International plc do?
Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.
What does Endo International plc's logo look like?
Complete history of Mr. Hyatt stock trades at Endo International plc
Endo International plc executives and stock owners
Endo International plc executives and other stock owners filed with the SEC include:
-
Paul Campanelli,
Chairman of the Board -
Terrance Coughlin,
Chief Operating Officer, Executive Vice President -
Blaise Coleman,
Pres, CEO & Director -
Blaise Coleman,
President, Chief Executive Officer, Director -
Matthew Maletta,
Executive Vice President, Chief Legal Officer -
Patrick Barry,
Executive Vice President and Chief Commercial Officer, U.S. Branded Business -
Patrick A. Barry,
Exec. VP & Pres of Global Commercial Operations -
Mark T. Bradley,
Exec. VP & CFO -
Roger Kimmel,
Senior Independent Director -
Shane Cooke,
Independent Director -
William Montague,
Independent Director -
Nancy Hutson,
Independent Director -
Michael Hyatt,
Independent Director -
M. Christine Smith,
Independent Director -
Mark Barberio,
Independent Director -
Jack Boyle,
Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer, Controller -
Rahul Garella,
Executive Vice President, International Pharmaceuticals -
Domenico Ciarico,
Executive Vice President and Chief Commercial Officer, Sterile and Generics -
Joseph A. Barbarite,
Exec. VP of Global Quality and Compliance -
Tracy Basso,
Chief HR Officer -
Susan Williamson,
Sr. VP & Chief Compliance Officer -
Laure E. Park,
Sr. VP of Investor Relations & Corp. Affairs -
Ruth Thorpe,
Sr. VP of Information Technology & Chief Information Officer -
Robert Polke,
Exec. VP & Global Head of Operations -
Arthur J Higgins,
Director -
Douglas S Ingram,
Director -
Hemanth Jacob Varghese,
Pres. International Pharma -
Suketu Upadhyay,
EVP, Chief Financial Officer -
Antonio R Pera,
President, Par Pharmaceutical -
Joseph Ciaffoni,
President, U.S. Branded Pharma -
Carrie Ann Nichol,
SVP, Controller & CAO -
Mark T. Bradley,
EVP, Chief Financial Officer -
Frank B. Raciti,
VP, Controller and CAO -
Daniel Rudio,
Vice President, Controller -
Sharad Mansukani,
Director -
William Spengler,
Director -
Silva Rajiv De,
President & CEO -
John Delucca,
Director -
Brian Lortie,
President Branded Pharma -
Susan Hall,
EVP, CSO, Global Head of R&D -
Caroline B Manogue,
Exec. V.P., CLO & Secy -
Camille Farhat,
President, AMS, Inc. -
Ivan P. Gergel,
EVP, R&D and CSO -
Donald W De Golyer,
Chief Operating Officer,Pharma -
Mary Christine Smith,
Director -
George Apostol,
EVP, Global R&D -
Jennifer M Chao,
Director -
James Patrick Tursi,
Executive VP, Global R&D